Sexual Dysfunction News and Research

Latest Sexual Dysfunction News and Research

Urologists report success in treating bladder issues, pelvic pain through neuromodulation technique

Millions of people suffer from bladder dysfunction, including about 30 million in the U.S. One in seven women experience chronic pelvic pain. These are not only health issues, but quality of life issues.

18 Aug 2015

Lidocaine benefits breast cancer survivors who experience pain during intercourse

Scientists at Oregon Health & Science University report that breast cancer survivors who experience pain during sexual intercourse, a common side effect of breast cancer treatment, may achieve comfort when liquid lidocaine is applied strategically to prevent pain.

28 Jul 2015

Scott & White Healthcare - Round Rock now offers fully integrative medicine services to Central Texans

Scott & White Healthcare - Round Rock is now offering integrative medicine services to Central Texans that include massage therapy and acupuncture at two of its regional clinics: Scott & White Clinic - Avery Ranch and Baylor Scott & White Clinic - Round Rock South.

21 Jul 2015

New UTMB study finds no association between testosterone therapy and blood clots in veins

A new study from The University of Texas Medical Branch at Galveston of more than 30,000 commercially insured men is the first large comparative analysis to show that there is no link between testosterone therapy and blood clots in veins. The study found that middle-aged and older men who receive testosterone therapy are not at increased risk of this illness.

21 Jul 2015

Psychosocial factors linked to pain in multiple sclerosis

Psychosocial factors are important and potentially modifiable determinants of persistent pain in patients with multiple sclerosis who are taking pain medication, research shows.

16 Jul 2015

Loyola offers holistic approach to help couples manage their sexual health

Cancer and cancer therapies are frequently associated with sexual dysfunction, yet this condition often goes untreated, according to specialists at Loyola Medicine's Sexual Wellness Clinic.

1 Jul 2015

Can-Fite reports further progress in continuing preclinical program of CF602 sexual dysfunction drug

Can-Fite BioPharma Ltd., a biotechnology company with a pipeline of proprietary small molecule drugs that address inflammatory and cancer diseases, today reported further progress in its continuing preclinical program of its CF602 drug candidate as the Company prepares to file an investigational new drug (IND) application with the U.S. Food and Drug Administration to allow the initiation of a Phase I clinical study.

29 Jun 2015

The Miriam Hospital offers new surgical treatment for benign prostatic hyperplasia

The Minimally Invasive Urology Institute at The Miriam Hospital is offering UroLift as one of the newest surgical treatments available for men with benign prostatic hyperplasia (BPH), an enlarged prostate condition.

23 Jun 2015

Low heart rate variability may place women at risk for sexual dysfunction

Chances are good that women with a low heart rate variability also suffer from sexual dysfunction. That's the finding from a study led by Amelia Stanton of The University of Texas at Austin in the US published in Springer's journal Applied Psychophysiology and Biofeedback.

17 Jun 2015

Can-Fite BioPharma receives Notice of Allowance for patent covering manufacturing method of CF101 drug

Can-Fite BioPharma Ltd., a biotechnology company with a pipeline of proprietary small molecule drugs being developed to treat inflammatory diseases, cancer and sexual dysfunction, today announced the U.S. Patent & Trademark Office has issued a Notice of Allowance to the Company for an important manufacturing method patent for its drug candidate CF101.

10 Jun 2015

Study shows increased sexual dysfunction in women following gynecologic cancer treatment

A University of Colorado Cancer Center study presented at the American Society for Clinical Oncology (ASCO) Annual Meeting 2015 shows decreased sexual activity in women following treatment for gynecologic cancers, down from 6.1-6.8 times per month before treatment to 2.6-4.9 times per month after treatment.

30 May 2015

Can-Fite BioPharma reports Q1 2015 financial results, provides updates on drug development programs

Can-Fite BioPharma Ltd., a biotechnology company with a pipeline of proprietary small molecule drugs being developed to treat inflammatory diseases, cancer and sexual dysfunction, today reported financial results for the three months ended March 31, 2015 and updates on its drug development programs.

29 May 2015

Endo Pharmaceuticals supports efforts to bring first ever treatment guidelines for Peyronie's Disease

Endo Pharmaceuticals Inc., a subsidiary of Endo International plc, supports efforts to bring the medical community the first ever treatment guidelines for Peyronie's Disease (PD), a condition in which collagen plaque, or scar tissue, develops on the shaft of the penis, and may harden and reduce flexibility.

19 May 2015

Can-Fite receives EMA clearance to begin CF102 Phase II trial for treatment of HCC patients in Europe

Can-Fite BioPharma Ltd., a biotechnology company with a pipeline of proprietary small molecule drugs being developed to treat inflammatory diseases, cancer and sexual dysfunction, today announced it recently received clearance from the European Medicines Agency to commence dosing patients in Europe in its global Phase II trial for CF102 in the treatment of hepatocellular carcinoma (HCC), the most common form of liver cancer.

11 May 2015

Only few sexually assaulted servicewomen seek post-assault health care, study finds

Despite growing public awareness of sexual assault of women during their military service and increased efforts by the Department of Defense to deter sexual crimes and encourage reporting and help-seeking, a Veterans Affairs study suggests most female service members who experience sexual assault are still unlikely to seek post-assault health care, at least in the short term.

29 Apr 2015

Can-Fite announces favorable data from further analysis of CF101 Phase II/III study in patients with psoriasis

Can-Fite BioPharma Ltd. (NYSE MKT: CANF) (TASE: CFBI), a biotechnology company with a pipeline of proprietary small molecule drugs that address inflammatory and cancer diseases, announced today favorable data from further analysis of its Phase II/III double-blind, placebo-controlled study designed to test the efficacy of CF101 in patients with moderate-to-severe plaque psoriasis.

27 Apr 2015

Can-Fite seeks EMA Orphan Drug Designation for CF102 in HCC

Can-Fite BioPharma Ltd., a biotechnology company with a pipeline of proprietary small molecule drugs that are being developed to treat inflammatory diseases, cancer and sexual dysfunction, announced today it has submitted an application to the European Medicines Agency for Orphan Drug Designation for its drug candidate CF102 in the treatment of hepatocellular carcinoma (HCC), the most common form of liver cancer.

20 Apr 2015

Loyola takes holistic approach to help couples manage their sexual health

Sexual dysfunction is common among couples, yet it often goes untreated, according to specialists at Loyola University Health System's Sexual Wellness Clinic.

1 Apr 2015

Investigational S-equol nutritional supplement may alleviate certain menopause symptoms

The investigational S-equol nutritional supplement may be a viable agent to alleviate certain menopause symptoms, such as hot flashes, according to a new peer-reviewed article in the March Journal of Women's Health.

30 Mar 2015

Can-Fite BioPharma's CF101Phase II/III psoriasis trial fails to meet primary endpoint

Can-Fite BioPharma Ltd., a biotechnology company with a pipeline of proprietary small molecule drugs that address inflammatory and cancer diseases, announced today that its Phase II/III psoriasis trial for the Company's drug candidate CF101 did not achieve its primary endpoint.

30 Mar 2015

Sexual Dysfunction News and Research

Latest Sexual Dysfunction News and Research

Urologists report success in treating bladder issues, pelvic pain through neuromodulation technique

Lidocaine benefits breast cancer survivors who experience pain during intercourse

Scott & White Healthcare - Round Rock now offers fully integrative medicine services to Central Texans

New UTMB study finds no association between testosterone therapy and blood clots in veins

Psychosocial factors linked to pain in multiple sclerosis

Loyola offers holistic approach to help couples manage their sexual health

Can-Fite reports further progress in continuing preclinical program of CF602 sexual dysfunction drug

The Miriam Hospital offers new surgical treatment for benign prostatic hyperplasia

Low heart rate variability may place women at risk for sexual dysfunction

Can-Fite BioPharma receives Notice of Allowance for patent covering manufacturing method of CF101 drug

Study shows increased sexual dysfunction in women following gynecologic cancer treatment

Can-Fite BioPharma reports Q1 2015 financial results, provides updates on drug development programs

Endo Pharmaceuticals supports efforts to bring first ever treatment guidelines for Peyronie's Disease

Can-Fite receives EMA clearance to begin CF102 Phase II trial for treatment of HCC patients in Europe

Only few sexually assaulted servicewomen seek post-assault health care, study finds

Can-Fite announces favorable data from further analysis of CF101 Phase II/III study in patients with psoriasis

Can-Fite seeks EMA Orphan Drug Designation for CF102 in HCC

Loyola takes holistic approach to help couples manage their sexual health

Investigational S-equol nutritional supplement may alleviate certain menopause symptoms

Can-Fite BioPharma's CF101Phase II/III psoriasis trial fails to meet primary endpoint

How the Vutara VXL simplifies single-molecule imaging

How cohesin mechanics and nanotracker tech are redefining DNA research

Todd Bauman and Chris Povich

Sexual Dysfunction News and Research

Latest Sexual Dysfunction News and Research

How the Vutara VXL simplifies single-molecule imaging

How cohesin mechanics and nanotracker tech are redefining DNA research

Todd Bauman and Chris Povich

Newsletters you may be interested in